Neuroscience Bulletin
May 21, 2026
Noah Cavallaro, Priya Rai, David Akins et al.
Mescaline, a 5-HT2A agonist psychedelic used ceremonially for millennia, lacks neuroimaging characterization due to its Schedule 1 status. Using pharmacological and resting-state fMRI in awake rats, we report mescaline's first comprehensive neurobiological profile. Acutely, mescaline produced cerebellar-selective BOLD suppression, suggesting functional disconnection from forebrain structures....
Neuropharmacology
March 6, 2026
Noah Cavallaro, Priya Rai, David Akins et al.
1 citation
To our knowledge, this is the first fMRI characterization of 5-MeO-DMT in any species, and it reveals a previously unreported sex difference in psychedelic response. The rapid onset and brief duration of peak effects align with 5-MeO-DMT's unique pharmacological profile and clinical reports.
Neuropsychopharmacology
February 18, 2026
Itishree Sahoo, Sairam Masadi, Ashwath Maheswari et al.
3 citations
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. Underlying these effects are changes in brain neuroplasticity. We hypothesized psilocybin given during adolescence, a time of heightened neuroplasticity, particularly in the forebrain, would affect emotional behavior and the associated underlying neuroanatomy, neurocircuitry, and epigenetics. Female and male mice...
Fahd François Hilal, Rayane Benkeddada, Jeanblanc Jérôme et al.
Background Classical psychedelics induce profound changes in brain function, yet the temporal organization of these effects remains incompletely understood. Methods We investigated the effects of acute lysergic acid diethylamide (LSD) on large-scale brain connectivity in nine male Long–Evans rats using resting-state functional magnetic resonance imaging. Following a 15-min baseline acquisition,...